Revolution Medicines, Inc.

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Role: lead

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Role: lead

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Role: collaborator

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Role: lead

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Role: lead

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Role: lead

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Role: collaborator

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Role: lead

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Role: lead

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Role: lead

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Role: lead

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Role: lead

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Role: lead

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Role: lead

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Role: lead

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Role: lead

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Role: collaborator

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Role: lead

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Role: lead

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Role: lead